Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Notes Payables (2018 - 2025)

International Stem Cell (ISCO) has disclosed Notes Payables for 7 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables fell 1.55% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 1.55% decrease, with the full-year FY2024 number at $3.4 million, down 1.79% from a year prior.
  • Notes Payables was $3.3 million for Q3 2025 at International Stem Cell, up from $3.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.5 million in Q2 2024 to a low of $2.9 million in Q1 2021.
  • A 5-year average of $3.3 million and a median of $3.3 million in 2022 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: rose 19.08% in 2021, then decreased 7.18% in 2025.
  • International Stem Cell's Notes Payables stood at $2.9 million in 2021, then grew by 12.98% to $3.3 million in 2022, then rose by 3.97% to $3.5 million in 2023, then dropped by 1.79% to $3.4 million in 2024, then fell by 2.65% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Notes Payables are $3.3 million (Q3 2025), $3.3 million (Q2 2025), and $3.4 million (Q1 2025).